Hong Kong Baptist University: Institute for Innovation, Translation and Policy Research
- Academic, tech transfer
- Biotech – food & agriculture
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- Diagnostics
- Medical device or technology
- Institute, hospital research
- Digital health
- Synthesis, analytic, diagnostic services
The Institute for Innovation, Translation and Policy Research (ITPR) of Hong Kong Baptist University (HKBU) helps to translate our university and affiliated spin-out company's products and assets. Clinical stage assets include: An automatic point-of-care multiplexing molecular diagnostic platform device that has already gained OUS market authorization; An FDA phase 2A oral dose for chronic constipation; A phase 3 ready nasal formulation for cancer patients with post-treatment breakthrough nausea / vomiting. Other innovations: A multiple APIs formulation involving p-gp inhibitor for treatment of metabolic diseases; and various assets such as biologics for thrombocytopenia, vaccines for animal health and oral formulation for IBD.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}